Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).

导出 OA

翻译打印收藏纠错

作者： Simon J,Crabb ^[1] ; Sarah,Danson ^[2] ; James W F,Catto ^[3] ; Syed,Hussain ^[4] ; Danna,Chan ^[5] ; Denise,Dunkley ^[4] ; Nichola,Downs ^[6] ; Ellice,Marwood ^[7] ; Laura,Day ^[2] ; Geoff,Saunders ^[3] ; Michelle,Light ^[7] ; Amy,Whitehead ^[2] ; Deborah,Ellis ^[7] ; Naveed,Sarwar ^[2] ; Deborah,Enting ^[7] ; Alison,Birtle ^[2] ; Bernadette,Johnson ^[7] ; Robert,Huddart ^[2] ; Gareth,Griffiths ^[7]

作者单位： Southampton Clinical Trials Unit, University of Southampton, Southampton, England, United Kingdom. S.J.Crabb@southampton.ac.uk. ^[1] University Hospital Southampton NHS Foundation Trust, Southampton, England, United Kingdom. ^[2] Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, England, United Kingdom. ^[3] Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, University of Sheffield, Sheffield, England, United Kingdom. ^[4] Academic Urology Unit, University of Sheffield, Sheffield, England, United Kingdom. ^[5] Astex Pharmaceuticals, Inc., Pleasanton, California. ^[6] Southampton Clinical Trials Unit, University of Southampton, Southampton, England, United Kingdom. ^[7] Department of Oncology, Charing Cross Hospital, London, England, United Kingdom. ^[8] Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, England, United Kingdom. ^[9] Lancashire Teaching Hospitals NHS Foundation Trust, Preston, England, United Kingdom. ^[10] The Institute of Cancer Research, Sutton, England, United Kingdom. ^[11]